版本:
中国

BRIEF-Aralez announces FDA approval of Yosprala for secondary prevention of cardiovascular and cerebrovascular events in patients at risk for aspirin-associated gastric ulcers

Sept 15 Aralez Pharmaceuticals Inc

* Announces FDA approval of YOSPRALA for secondary prevention of cardiovascular and cerebrovascular events in patients at risk for aspirin associated gastric ulcers

* Aralez Pharmaceuticals Inc says YOSPRALA U.S. commercial launch planned for first week of october

* Each study achieved its individual primary endpoint

* Aralez Pharmaceuticals Inc says Aralez sales force will be expanded by 85 to 110 sales representatives by launch

* Says studies demonstrate yosprala clinical benefit Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐